Antifibrotic drug development · Patent pending

Developing intravenous antifibrotic therapy for advanced liver fibrosis

IRA Med Rx is building the first intravenous formulation of pirfenidone, a proven antifibrotic molecule, for patients with advanced liver disease who need more than oral therapy can offer.

Partner with us Our science
0FDA-approved drugs for liver cirrhosis
Firstintravenous pirfenidone program
3organs targeted: liver, kidney, lung
IV Targeting fibrosis Controlled dosing

The unmet need

Liver fibrosis is the scarring that drives chronic liver disease toward cirrhosis and liver failure. The first FDA approvals (2024–2025) cover only non-cirrhotic MASH with fibrosis. No drug is approved for cirrhosis, and most causes of liver fibrosis still have no antifibrotic treatment.

No therapy for cirrhosis

Treatment today targets the underlying cause. For patients who have reached cirrhosis, there is no approved drug that reverses liver scarring.

The sickest can't take pills

Hospitalized patients with advanced disease often cannot reliably take oral medication because of nausea, vomiting or confusion.

Transplant is limited

Liver transplant remains the last option for end-stage disease, and organs are scarce. New therapies are urgently needed.

Our science

Pirfenidone is an established antifibrotic and anti-inflammatory molecule. We are developing it as an intravenous therapy for controlled, monitored dosing in advanced liver disease.

The liver is both the target organ and the site where pirfenidone is metabolized. Our formulation work focuses on achieving steady, therapeutic exposure through continuous infusion or a sustained-release intravenous form.

DRUG LEVEL IN BLOOD (concept) Oral doses: peaks and drops IV infusion: steady level
  • Oral pirfenidone is FDA-approved for idiopathic pulmonary fibrosis.
  • A prolonged-release oral form is approved for liver fibrosis in Mexico.
  • Clinical studies of oral pirfenidone in advanced liver fibrosis have reported reductions in fibrosis markers.
  • No intravenous form of pirfenidone has yet been tested in humans. That is the gap we are working to close.

Pipeline

Our lead program is intravenous pirfenidone for advanced liver fibrosis. Kidney and lung fibrosis are potential future indications.

ProgramIndicationStage
IV Pirfenidone
Lead program
Advanced liver fibrosis Formulation development
FormulationPreclinicalPhase 1Phase 2Phase 3
IV Pirfenidone Kidney fibrosis Exploratory
IV Pirfenidone Lung fibrosis Exploratory
From the lab to patients

Development and clinical trial plan

Every new medicine in the United States follows the same FDA path. Here is each stage IV pirfenidone is planned to go through, what happens in it, and why it matters. Timelines are typical estimates and depend on study results and funding.

Formulation
Preclinical
IND
Phase 1
Phase 2
Phase 3
FDA review
  1. 1

    Formulation development

    Current stage
    Duration about 6–12 monthsWhere contract laboratory

    Goal: create a sterile, stable liquid form of pirfenidone that can be safely given into a vein.

    • Test how much pirfenidone dissolves and at what pH it stays stable.
    • Design for continuous infusion or a sustained-release form, because pirfenidone is cleared from the body quickly.
    • Confirm sterility and shelf life, then produce small laboratory batches for testing.
  2. 2

    Preclinical studies

    Planned
    Duration about 1–2 yearsWhere laboratory and animal studies

    Goal: show that the drug reaches the liver, reduces scarring, and is safe enough to test in people.

    • Pharmacokinetics: how long the drug stays in the blood and how much reaches the liver.
    • Efficacy: whether IV pirfenidone reduces fibrosis in established liver-scarring models.
    • Toxicology: formal safety studies in two species to define safe doses, as required by the FDA.
    • Manufacturing: a clinical-grade (GMP) batch made by a sterile-injectables manufacturer.
  3. 3

    IND application to the FDA

    Planned
    Duration 30-day FDA reviewWho FDA

    Goal: receive permission to give the drug to humans.

    • Submit the formulation, manufacturing details, all animal data, and the proposed human trial plan.
    • A pre-IND meeting with the FDA comes first, to agree on what the agency needs to see.
    • If the FDA does not object within 30 days, the first clinical trial may begin.
  4. 4

    Phase 1 clinical trial

    Planned
    Duration about 1 yearParticipants about 15–40 patients

    Key question: is it safe, and what is the right dose?

    • Patients receive the drug starting at a low dose, which is increased step by step.
    • Doctors closely monitor side effects, liver tests and drug levels in the blood.
    • Because pirfenidone is processed by the liver, dosing in liver disease starts low and is monitored carefully.
  5. 5

    Phase 2 clinical trial

    Planned
    Duration about 1–2 yearsParticipants about 60–200 patients

    Key question: does it work?

    • Patients with advanced liver fibrosis receive the drug or standard care for comparison.
    • Doctors measure changes in fibrosis markers, liver stiffness, liver function and quality of life.
    • Positive results here are the foundation for larger trials and partnerships.
  6. 6

    Phase 3 clinical trial

    Planned
    Duration about 2–4 yearsParticipants hundreds of patients

    Key question: does it beat standard care in a large population?

    • A large study across multiple hospitals confirms the benefit seen in Phase 2.
    • It also detects rarer side effects that smaller studies can miss.
  7. 7

    FDA review and approval (NDA)

    Planned
    Duration about 1 year of reviewWho FDA

    Goal: approval to make the medicine available to patients.

    • All manufacturing, safety and effectiveness data are submitted in a New Drug Application.
    • If approved, doctors can prescribe IV pirfenidone to patients who need it.

IV pirfenidone is investigational and has not been tested in humans. No clinical trial is currently enrolling.

Partners

We are forming our network of research, development and clinical partners. We welcome conversations with:

Academic research partners

Liver fibrosis laboratories and hepatology programs interested in preclinical studies and NIH STTR collaboration.

Development partners

Sterile injectable CDMOs and contract research organizations for formulation, pharmacokinetics and toxicology.

Advisors and investors

Scientific advisors, clinicians and investors who share our goal of bringing a new antifibrotic therapy to patients.

About IRA Med Rx

IRA Med Rx LLC is a founder-led pharmaceutical company focused on antifibrotic therapies. Our mission is to give patients with advanced organ fibrosis a chance to preserve their own organs.

Founder & CEO

Olivia Lee

Olivia founded IRA Med Rx to develop new delivery forms of pirfenidone for patients with fibrotic disease. She leads the company's intellectual property, regulatory and development strategy.

Contact

For partnership, research collaboration or investor inquiries, please reach out.

Emailinfo@iramedrxbio.com

Phone+1 (561) 884-5626

Address1209 Mountain Rd Pl NE, Ste R
Albuquerque, NM 87110, USA